EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased ...

Despite a decline in total revenue, Edap TMS SA (EDAP) reports significant growth in its HIFU segment and outlines optimistic projections for 2026.

EDAP management highlighted what it sees as a growing global opportunity for therapeutic ultrasound in urology, emphasizing ...

MD Anderson at Cooper has expanded its prostate cancer treatment program with the addition of robotic high-intensity focused ultrasound, a groundbreaking therapy designed to treat tumors without ...

Q4 2025 Management View CEO Ryan Rhodes described 2025 as a transformative year, highlighting "39% revenue growth in our core HIFU business and record commercial performance for Focal One." Rhodes ...

Edap Tms S.a. (NASDAQ:EDAP) Q4 2025 Earnings Call Transcript March 25, 2026 Edap Tms S.a. misses on earnings expectations.

AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) ...

THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, ...

Seasoned medical technology sales and marketing professional brings more than 25 years of experience to the EDAP team Joins EDAP from Exact Imaging to lead the recently announced global distribution ...

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, ...